Pre-Market Money Movers

by @tabber

NOV 17, 2026

AYTU — +44% premarket as Rosemont agrees $2.70/share cash buyout

AYTU+44% upDeal

Rosemont Pharmaceuticals agreed to acquire Aytu BioPharma in an all-cash tender offer at $2.70 per share, a 41.1% premium to Aytu’s 30-day volume-weighted average price and 51.7% above Friday’s close, valuing the deal at about $56 million. Aytu’s board unanimously approved the agreement, with closing expected in late December 2026. The deal gives Rosemont Aytu’s ADHD portfolio and an emerging depression asset alongside a U.S. commercial platform.

Read full analysis on globenewswire.com ↗
Useful?